Real-life use and effectiveness of adjuvant trastuzumab in early breast cancer patients: A study of the Southeast Netherlands breast cancer consortium

Oncologist

Volumn 20, Issue 8, 2015, Pages 856-863

  Seferina, Shanly C ^a,b   Lobbezoo, Dorien J A ^a,b,c   De Boer, Maaike ^a,b   Dercksen, M Wouter ^c   Van Den Berkmorte, Franchette ^d   Van Kampen, Roel J W ^a,d   Van De wouw, Agnès J ^e   De Vries, Bart ^a   Joore, Manuela A ^a,b   Peer, Petronella G M ^a,f   Voogd, Adri C ^a,b   Tjan Heijnen, Vivianne C G ^a,b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MÁXIMA MEDICAL CENTER   (Netherlands)

^d Zuyderland Medical Centre   (Netherlands)

^e VIECURI MEDICAL CENTER   (Netherlands)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Early breast cancer; Effectiveness; Real life; Trastuzumab

Indexed keywords

TRASTUZUMAB; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CARDIOTOXICITY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; EARLY CANCER; HUMAN; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; COHORT ANALYSIS; FEMALE; MIDDLE AGED; NETHERLANDS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; NETHERLANDS; TRASTUZUMAB;

EID: 84940026958     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0006     Document Type: Article

References (21)

1. Richtlijn mammacarcinoom version 2.0 Consensus based 2012-02-13. Available at http://www.oncoline.nl. 2012. Accessed February 24,2012.
2. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. NEngl JMed 2005;353: 1659–1672.
3. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673–1684.
4. Slamon D, Eiermann W, Robert N et al. Adjuvant trastuzumab in HER2-positive breast cancer. NEngl J Med 2011;365:1273–1283.
5. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. NEngl JMed 2006;354:809–820.
6. Spielmann M, Rochè H, Delozier T et al. Trastuzumab for patients with axillary-node-positive breast cancer: Results of the FNCLCC-PACS 04 trial. J Clin Oncol 2009;27:6129–6134.
7. Vos EJ, Linn SC,Rodenhuis S. [Effects and costs of adjuvant chemotherapy for operable lymph node positive breast cancer with HER2/neu overexpression]. Ned Tijdschr Geneeskd 2006;150:776–780.
8. Curigliano G, Viale G, Bagnardi V et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 2009;27:5693–5699.
9. Gonzalez-Angulo AM, Litton JK, Broglio KR et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 2009;27:5700–5706.
10. Gnant M, Harbeck N, Thomssen C. St. Gallen 2011: Summary of the ConsensusDiscussion. Breast Care (Basel) 2011;6:136–141.
11. Richtlijn “Behandeling van het Mammacarcinoom.” Utrecht, The Netherlands: Kwaliteitsinstituut voor de Gezondheidszorg CBO/Vereniging van Integrale Kankercentra en Nationaal Borstkanker Overleg Nederland (NABON), 2005.
12. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373–383.
13. de Munck L, Schaapveld M, Siesling S et al. Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of nonmetastatic breast cancer in the Netherlands. Breast Cancer Res Treat 2011;129:229–233.
14. Perez EA, Romond EH, Suman VJ et al. Fouryear follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011;29:3366–3373.
15. Whitfield R, Kollias J, De Silva P et al. Use of trastuzumab in Australia and New Zealand: Results from the National Breast Cancer Audit. ANZ J Surg 2012;82:234–239.
16. Liebrich C, Unger G, Dlugosch B et al. Adopting guidelines into clinical practice: Implementation of trastuzumab in the adjuvant treatment of breast cancer in Lower Saxony, Germany, in 2007. Breast Care (Basel) 2011;6:43–50.
17. Gianni L, Dafni U, Gelber RD et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: A 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011;12:236–244.
18. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118–145.
19. Seal MD, Speers CH, O’Reilly S et al. Outcomes of women with early-stage breast cancer receiving adjuvant trastuzumab. Curr Oncol 2012;19:197–201.
20. Smith I, Procter M, Gelber RD et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 2007;369:29–36.
21. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): An openlabel, randomised controlled trial. Lancet 2013;382: 1021–1028.